Kazia (KZIA) Net earnings per share growth forecast for next year

Corporate company logo of Kazia Therapeutics Limited (KZIA)

Experienced management with deep R&D expertise ensures the steady development of Kazia Therapeutics (KZIA), which is reflected in the price action. The projected growth rate of net income per share visualizes the institutional development vector. Meanwhile, -56.30 determines the current status of the parameter. The business model relies on outsourcing brain tumor tests and fully transferring production to external contractors to minimize capital expenditures.

Kazia (KZIA): Net earnings per share growth forecast for next year from 07/04/2022 to 11/18/2026

Summary analytical data breakdowns for Kazia Therapeutics (KZIA)

- share price and consensus valuation forecast:
Fundamental company analysis:Kazia Therapeutics Ltd
Finished products of Kazia

The narrow specialization of Kazia Therapeutics (KZIA) in treating glioblastomas makes its financial results dependent on clinical trial outcomes. When analyzing the expected EPS trend for the coming year, an investor assesses the consensus earnings per share forecast, which serves as an indicator of cash flow predictability and a safeguard against overpaying for an asset with high fundamental volatility.

Competitor analysis for Kazia Therapeutics

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology Inc.)|BYSI (BeyondSpring) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (Lixte Biotechnology Holdings, Inc.)|Citius Pharmaceuticals, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year canfite.com (CANF)|Net earnings per share growth forecast for next year aprea.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)